Back to results
US 2004/0081616 A1Published application
Pendant fatty acid imaging agents
AssigneeBiostream, Inc.
InventorsJohn W. Babich, Kevin P. Maresca
Life of this patent
Estimating the term…
Abstract
The disclosure provides pendant fatty acid compounds for use in diagnostic imaging, (particularly the cardiovascular system), as well as kits comprised of the same. The disclosure also provides for a method administering a imaging agent with a high specificity for the myocardium.
Claims27
An imaging agent represented by the structure 1:
- 20
- wherein
- R1, R4, R5, and R6 are each independently selected from an alkyl, alkenyl or a bond;
- R2 is selected from the group consisting of a hydrogen, a primary amine, a secondary amine, a tertiary amine, an alkyl group, a substituted alkyl group, an aryl group, and a substituted aryl group;
- R3 is selected from the group consisting of a hydrogen, an alkyl, a hydroxyl, a keto ester, an alkoxy, a halide, and an amine;
- R7 is selected from a metal chelating moiety bound to a metallic carbonyl ligand;
- wherein the stereochemical configuration of a compound represented by 1 may be R, S, at the stereocenters;
- or a mixture of these configurations, and
- and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
6 more elements
An imaging agent represented by the structure 2:
- 21
- wherein
- R1, R4, R5, and R6 are each independently selected from an alkyl, alkenyl or a bond;
- R2 is selected from the group consisting of a hydrogen, a primary amine, a secondary amine, a tertiary amine, an alkyl group, a substituted alkyl group, an aryl group, and a substituted aryl group;
- R3 is selected from the group consisting of a hydrogen, an alkyl, a hydroxyl, a keto ester, an alkoxy, a halide, and an amine;
- R7 is selected from:
- 22
- R8 is selected from the group O, H, OH, alkoxy, or O-alkyl;
- R9 is any heterocycle;
- R10 and R11 are each independently hydrogen, alkyl or substituted alkyl;
- R12 is selected from the group of aryl, alkyl, or heterocycle;
- the stereochemical configuration of a compound represented by 2 may be R or S, at the stereocenters;
- or a mixture of these configurations, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
10 more elements
The imaging agent represented by the compound:
- 23
- wherein
- R3 is H or alkyl;
- R7 is selected from
- 24
- R8 is selected from the group O, H, OH, alkoxy, or O-alkyl;
- m is an integer between 0 and 12 inclusive;
- n is an integer between 0 and 12 inclusive;
- p is an integer between 0 and 12 inclusive;
- wherein a stereochemical configuration of a compound represented by 3 may be R or S, at the stereocenters;
- or a mixture of these configurations;
- and
- the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
10 more elements
The imaging agent represented by the compound:
- 25
- wherein
- R7 is selected from
- 26
- R8 is selected from the group O, H, OH, alkoxy, or O-alkyl;
- m is an integer selected from 0 to 12;
- p is an integer selected from 0, 1, 2, 4, 6 or 8, wherein a stereochemical configuration of a compound represented by 4 may be R or S, at the stereocenters;
- or a mixture of these configurations;
- and
- the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
7 more elements
A method of identifying a cardiovascular lesion comprising:
- administering an imaging agent to a subject;
- wherein said imaging agent shows a heart to blood ratio of at least about 3 to 1 and at least about 0.3% ID/g heart retention within about 60 minutes of administration.
Dependencies are inferred from the claim text.